Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ibrutinib in CNS Lymphoma
NCT03770416Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2019
- Primary completion
- Feb 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, nivolumab in central nervous system lymphoma, sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2019; status: completed.
02
Drugs
ibrutinibnivolumab
03
Conditions
central nervous system lymphoma
Beyond the preview
Go deeper on NCT03770416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03770416.